Diagnoptics announces that it has been granted a Japan and EU patent for a method for skin colour independent assessment of Advanced Glycation Endproducts.
A method for skin colour independent assessment of skin Advanced Glycation Endproducts (by measuring autofluorescence) is essential in the international introduction of the AGE Reader technology. It allows Diagnoptics to protect its technological advances in non-invasively measuring tissue levels of Advanced Glycation Endproducts. The new patents reinforce that Diagnoptics is the pioneer and inventor of cutting edge diagnostic devices that can non-invasively diagnose and assess cardiovascular risk and the risk of diabetes.
The AGE Reader provides an immediate cardiovascular risk prediction for major chronic diseases, such as diabetes, cardiovascular disease and renal failure. The AGE Reader allows a Point-of-Care and non-invasive assessment of cardiovascular risk. The method is convenient, easy to use and validated. The AGE Reader measures tissue accumulation of Advanced Glycation Endproducts (AGEs) by means of fluorescence techniques (skin autofluorescence (skin AF)). AGEs play a key role in the pathogenesis of many age-related diseases, such as diabetes, cardiovascular disease and renal failure.
Diagnoptics was the first company worldwide to introduce a technology to non-invasively measure the tissue accumulation of AGEs by means of fluorescence techniques (AGE Reader). The AGE Reader has been used in clinical practice and research since 2006. Since the introduction of the AGE Reader over 140 peer reviewed scientific papers have been published.